Insights into implementation of sacubitril/valsartan into clinical practice.

about

Insights into implementation of sacubitril/valsartan into clinical practice.

Item

http://www.wikidata.org/entity/Q49718855

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Insights into implementation of sacubitril/valsartan into clinical practice.

@en

Insights into implementation of sacubitril/valsartan into clinical practice.

@nl

type

Item

label

Insights into implementation of sacubitril/valsartan into clinical practice.

@en

Insights into implementation of sacubitril/valsartan into clinical practice.

@nl

prefLabel

Insights into implementation of sacubitril/valsartan into clinical practice.

@en

Insights into implementation of sacubitril/valsartan into clinical practice.

@nl

P1476

Insights into implementation of sacubitril/valsartan into clinical practice.

@en

P2093

Hanne Beliën

http://www.w3.org/2001/XMLSchema#string

Matthias Dupont

http://www.w3.org/2001/XMLSchema#string

Pieter Martens

http://www.w3.org/2001/XMLSchema#string

Wilfried Mullens

http://www.w3.org/2001/XMLSchema#string

P2860

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.

Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.

The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.

Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.

Value of routine investigations to predict loop diuretic down-titration success in stable heart failure.

Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions.

P304

275-283

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EHF2.12258

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29464879

http://www.w3.org/2001/XMLSchema#string

P932

5933963

http://www.w3.org/2001/XMLSchema#string